Get the Stockscreener App
1.53
1.29%
-0.02
Lava Therapeutics Nv stock is traded at $1.53, with a volume of 181.48K.
It is down -1.29% in the last 24 hours and up +6.25% over the past month.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
See More
Previous Close:
$1.55
Open:
$1.541
24h Volume:
181.48K
Relative Volume:
2.50
Market Cap:
$40.25M
Revenue:
$9.06M
Net Income/Loss:
$-50.39M
P/E Ratio:
-0.7969
EPS:
-1.92
Net Cash Flow:
$5.89M
1W Performance:
+0.66%
1M Performance:
+6.25%
6M Performance:
+59.79%
1Y Performance:
-18.18%
1-Day Range:
$1.53
$1.5456
1-Week Range:
$1.51
$1.55
52-Week Range:
$0.8502
$2.093
Lava Therapeutics Nv Stock (LVTX) Company Profile
Name
Lava Therapeutics Nv
Sector
Industry
Phone
31 6 3000 3035
Address
YALELAAN 62, UTRECHT
Compare LVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LVTX
Lava Therapeutics Nv
|
1.53 | 39.98M | 9.06M | -50.39M | 5.89M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-25-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-21 | Initiated | JP Morgan | Overweight |
| Apr-19-21 | Initiated | Jefferies | Buy |
| Apr-19-21 | Initiated | SVB Leerink | Outperform |
View All
Lava Therapeutics Nv Stock (LVTX) Latest News
Using economic indicators to assess LAVA Therapeutics N.V. potential2025 Geopolitical Influence & Proven Capital Preservation Methods - Newser
How high can LAVA Therapeutics N.V. stock goJuly 2025 Recap & Safe Capital Investment Plans - Newser
Analyzing LAVA Therapeutics N.V. with multi timeframe chartsJuly 2025 Rallies & Low Drawdown Investment Strategies - Newser
Has LAVA Therapeutics N.V. found a price floor2025 Key Highlights & High Return Stock Watch Alerts - Newser
Using fundamentals and technicals on LAVA Therapeutics N.V.July 2025 Analyst Calls & Scalable Portfolio Growth Ideas - Newser
Is now a turning point for LAVA Therapeutics N.V.2025 Earnings Surprises & Daily Stock Trend Reports - Newser
Risk vs reward if holding onto LAVA Therapeutics N.V.July 2025 Levels & Weekly High Return Opportunities - Newser
Lava Therapeutics Reports Q2 2025 Financial Results - TipRanks
Is a relief rally coming for LAVA Therapeutics N.V. holdersJuly 2025 PreEarnings & Real-Time Buy Zone Alerts - Newser
Automated trading signals detected on LAVA Therapeutics N.V.Market Growth Report & Reliable Price Action Trade Plans - Newser
Is LAVA Therapeutics N.V. forming a bottoming baseJuly 2025 Market Mood & AI Driven Stock Price Forecasts - Newser
How to interpret RSI for LAVA Therapeutics N.V. stockTreasury Yields & Daily Oversold Stock Bounce Ideas - Newser
Sector Leaders Rotate Capital Into LAVA Therapeutics N.V.July 2025 Market Mood & Low Risk High Win Rate Picks - beatles.ru
LAVA Therapeutics N.V. Charts Flash Early Recovery SignalsPortfolio Risk Report & Fast Moving Stock Watchlists - newsimpact.co.kr
LAVA Therapeutics NV reports results for the quarter ended June 30Earnings Summary - TradingView
Signal strength of LAVA Therapeutics N.V. stock in tech scannersEarnings Beat & Technical Entry and Exit Alerts - Newser
Real time scanner hits for LAVA Therapeutics N.V. explainedTrade Risk Assessment & Growth Focused Entry Point Reports - Newser
Real time breakdown of LAVA Therapeutics N.V. stock performanceGap Up & Daily Profit Maximizing Trade Tips - Newser
What earnings revisions data tells us about LAVA Therapeutics N.V.Weekly Risk Summary & Fast Exit/Entry Strategy Plans - Newser
How Resilient Is LAVA Therapeutics N.V. Stock During Economic Downturns2025 Institutional Moves & AI Powered Market Trend Analysis - Newser
Is LAVA Therapeutics N.V. stock poised for growthJuly 2025 Short Interest & Fast Moving Stock Watchlists - Newser
When is the best time to exit LAVA Therapeutics N.V.Breakout Watch & Weekly High Return Stock Forecasts - Newser
Live market analysis of LAVA Therapeutics N.V.Market Performance Recap & Smart Swing Trading Alerts - Newser
Published on: 2025-08-16 20:35:46 - metal.it
Published on: 2025-08-16 07:09:38 - Newser
Will breakout in LAVA Therapeutics N.V. lead to full recoveryCEO Change & Consistent Profit Trade Alerts - Newser
Is it too late to sell LAVA Therapeutics N.V.Rate Hike & Breakout Confirmation Alerts - Newser
LAVA Therapeutics N.V. Rebounds From Oversold Zone — Now WhatJuly 2025 Fed Impact & Free Expert Approved Momentum Trade Ideas - 선데이타임즈
Why LAVA Therapeutics N.V. stock attracts strong analyst attentionWeekly Trend Report & AI Based Trade Execution Alerts - Newser
LAVA Therapeutics Announces Acquisition by XOMA Corporation - MSN
Moving Average Crossover Confirms Uptrend in LAVA Therapeutics N.V.2025 Volume Leaders & Real-Time Stock Entry Alerts - metal.it
Lava Therapeutics Nv Stock (LVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):